Non-Melanoma Skin Cancers

Long-term TNF inhibitor use was associated with significantly increased risks of melanoma and nonmelanoma skin cancer in a large cohort study.

Dermatologists and oncologists at a Dermatology Times Evolving Paradigms event in Dallas compared immunotherapy selection, adverse event management, and referral practices in advanced cutaneous squamous cell carcinoma.

Because BCC and cSCC have high tumor mutational burdens driven by UV-induced DNA damage, they are particularly well suited to immune checkpoint inhibition.

Australian multicenter data shows older head and neck squamous cell carcinoma patients often miss standard radiotherapy-plus-chemo, yet guideline care boosts survival.

Medicus seeks FDA orphan drug status for SkinJect, a dissolvable microneedle doxorubicin patch targeting Gorlin-related basal cell carcinomas, aiming to reduce the need for repeated surgery.

At AAD 2026, Todd Schlesinger, MD, highlighted how staging frameworks and clinicopathologic features can inform treatment decisions in nonmelanoma skin cancer.

New sunscreen filters, AI tools, and immunotherapies are reshaping skin cancer prevention and treatment, improving precision and long-term survival.

Although the number of women leaders in Mohs surgery has increased, significant gender disparities remain in leadership roles, productivity metrics, and speaking opportunities.

A multicenter trial in China shows ALA-PDT clears Bowen’s disease in 97% with low recurrence, minimal scarring, and high patient satisfaction.

A Winter Clinical Miami poster highlights intralesional cemiplimab for early CSCC, showing rapid responses and positive safety versus surgery.

Todd Schlesinger, MD, highlights data supporting red light–activated PDT with 10% ALA gel for superficial basal cell carcinoma, discussing structured treatment protocols and manageable tolerability.

The FDA has accepted Biofrontera’s supplemental new drug application seeking approval of Ameluz photodynamic therapy for superficial basal cell carcinoma (sBCC), with a decision expected by September 28, 2026.

Todd Schlesinger, MD, reviews emerging randomized trial data supporting red light–activated photodynamic therapy with 10% aminolevulinic acid gel and outlines key considerations for patient selection in superficial basal cell carcinoma (sBCC).

Todd Schlesinger, MD, discusses emerging evidence, clearance outcomes, and practical considerations for using red light–based photodynamic therapy as a nonsurgical option in select superficial basal cell carcinoma (BCC) cases.

Sun Pharma has launched cosibelimab-ipdl for advanced cutaneous squamous cell carcinoma, offering new hope for patients with limited treatment options.